Eisai Co. announced May 11 that its U.S. subsidiary Eisai Inc. has expanded the marketing and supply agreement it concluded with Arena Pharmaceuticals GmbH in July 2010 for the anti-obesity agent lorcaserin.
Although the original agreement granted Eisai the exclusive rights to market and distribute lorcaserin in the United States, subject to U.S. Food and Drug Administration approval, the expanded agreement now includes 20 countries throughout the Americas, including Mexico, Brazil and Canada.
Lorcaserin, originally discovered by Arena, is an investigational drug candidate being developed for weight management, including weight loss and maintenance of weight loss, in patients who are obese and have at least one weight-related co-morbid condition.
Lorcaserin is currently under review by the U.S. FDA, with an assigned Prescription Drug User Fee Act date of June 27, 2012, which is the date for the agency to complete its review.
- « Prev
- Next »